Drug Shortage Report for TEVA-ABACAVIR/LAMIVUDINE

Last updated on 2023-08-17 History
Report ID 195072
Drug Identification Number 02416662
Brand name TEVA-ABACAVIR/LAMIVUDINE
Common or Proper name TEVA-ABACAVIR/LAMIVUDINE
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) LAMIVUDINE ABACAVIR
Strength(s) 300MG 600MG
Dosage form(s) TABLET
Route of administration ORAL ORAL
Packaging size 100
ATC code J05AR
ATC description DIRECT ACTING ANTIVIRALS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-06-16
Estimated end date 2023-08-20
Actual end date 2023-07-17
Shortage status Resolved
Updated date 2023-08-17
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v15 2023-08-17 French Compare
v14 2023-08-17 English Compare
v13 2023-08-08 French Compare
v12 2023-08-08 English Compare
v11 2023-07-27 French Compare
v10 2023-07-27 English Compare
v9 2023-07-21 French Compare
v8 2023-07-21 English Compare
v7 2023-07-12 French Compare
v6 2023-07-12 English Compare
v5 2023-07-04 French Compare
v4 2023-07-04 English Compare
v3 2023-06-17 English Compare
v2 2023-06-16 French Compare
v1 2023-06-16 English Compare

Showing 1 to 15 of 15